{"title":"Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia","authors":"Nurhilal Büyükkurt, Barış Soydaş","doi":"10.4274/tjh.galenos.2023.2023-0109","DOIUrl":null,"url":null,"abstract":"Waldenstrom macroglobulinemia (WM) is a rare disorder [1]. The combination of rituximab and ibrutinib has been associated with prolonged progression-free survival in previously treated and untreated cases of WM [2]. Unfortunately, however, adverse effects due to off-target interactions are disadvantages of ibrutinib. In this context, we would like to present a case of pancreatitis in a patient undergoing ibrutinib treatment. The mechanism of pancreatitis may be direct toxicity, hypertriglyceridemia, or immune-mediated injury to the liver, pancreas, or blood supply by direct injection [3]. Although a single case of pancreatitis was reported in a phase 1/1b study that included 48 patients, ibrutinib-associated pancreatitis has not yet been reported in the literature as a real-life clinical experience [4].","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/ab/TJH-40-141.PMC10240158.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/tjh.galenos.2023.2023-0109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Waldenstrom macroglobulinemia (WM) is a rare disorder [1]. The combination of rituximab and ibrutinib has been associated with prolonged progression-free survival in previously treated and untreated cases of WM [2]. Unfortunately, however, adverse effects due to off-target interactions are disadvantages of ibrutinib. In this context, we would like to present a case of pancreatitis in a patient undergoing ibrutinib treatment. The mechanism of pancreatitis may be direct toxicity, hypertriglyceridemia, or immune-mediated injury to the liver, pancreas, or blood supply by direct injection [3]. Although a single case of pancreatitis was reported in a phase 1/1b study that included 48 patients, ibrutinib-associated pancreatitis has not yet been reported in the literature as a real-life clinical experience [4].
期刊介绍:
The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology.
The Editorial Board of The Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).
The aim of The Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, The Turkish Journal of Hematology does not accept case reports. Important new findings or data about interesting hematological cases may be submitted as a brief report.